Clusterin serum levels are elevated in patients with early rheumatoid arthritis and predict disease activity and treatment response

Abstract Clusterin (CLU) is a molecular chaperone that participates in a variety of biological processes. Recent studies indicate its possible involvement in the development of bone erosions and autoimmunity. The aim of this study was to investigate its serum concentrations in patients with early rh...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tereza Kropáčková, Heřman Mann, Olga Růžičková, Olga Šléglová, Lucia Vernerová, Veronika Horváthová, Michal Tomčík, Karel Pavelka, Jiří Vencovský, Ladislav Šenolt
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/227e667eadb7435baccf2f0805b6c601
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:227e667eadb7435baccf2f0805b6c601
record_format	dspace
spelling	oai:doaj.org-article:227e667eadb7435baccf2f0805b6c6012021-12-02T15:56:49ZClusterin serum levels are elevated in patients with early rheumatoid arthritis and predict disease activity and treatment response10.1038/s41598-021-90973-22045-2322https://doaj.org/article/227e667eadb7435baccf2f0805b6c6012021-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-90973-2https://doaj.org/toc/2045-2322Abstract Clusterin (CLU) is a molecular chaperone that participates in a variety of biological processes. Recent studies indicate its possible involvement in the development of bone erosions and autoimmunity. The aim of this study was to investigate its serum concentrations in patients with early rheumatoid arthritis (RA) and to explore their potential relationship with disease activity and treatment response. Serum levels of CLU were measured in 52 patients before and 3 months after the initiation of treatment and in 52 healthy individuals. CLU levels at baseline were significantly increased in patients with early RA compared with healthy subjects (p < 0.0001). After 3 months of treatment, the levels of CLU decreased and reached concentrations comparable to those in controls. Even though there was no relationship between CLU levels and disease activity at baseline, CLU levels positively correlated with disease activity at months 3, 6 and 12 after treatment initiation. Using ROC analysis, lower CLU baseline levels predicted achieving the therapeutic target of low disease activity and remission at months 3, 6 and 12. In summary, we found increased serum concentrations of clusterin in treatment-naïve patients with early rheumatoid arthritis, and we suggest clusterin as a predictive biomarker of disease activity and treatment response.Tereza KropáčkováHeřman MannOlga RůžičkováOlga ŠléglováLucia VernerováVeronika HorváthováMichal TomčíkKarel PavelkaJiří VencovskýLadislav ŠenoltNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Tereza Kropáčková Heřman Mann Olga Růžičková Olga Šléglová Lucia Vernerová Veronika Horváthová Michal Tomčík Karel Pavelka Jiří Vencovský Ladislav Šenolt Clusterin serum levels are elevated in patients with early rheumatoid arthritis and predict disease activity and treatment response
description	Abstract Clusterin (CLU) is a molecular chaperone that participates in a variety of biological processes. Recent studies indicate its possible involvement in the development of bone erosions and autoimmunity. The aim of this study was to investigate its serum concentrations in patients with early rheumatoid arthritis (RA) and to explore their potential relationship with disease activity and treatment response. Serum levels of CLU were measured in 52 patients before and 3 months after the initiation of treatment and in 52 healthy individuals. CLU levels at baseline were significantly increased in patients with early RA compared with healthy subjects (p < 0.0001). After 3 months of treatment, the levels of CLU decreased and reached concentrations comparable to those in controls. Even though there was no relationship between CLU levels and disease activity at baseline, CLU levels positively correlated with disease activity at months 3, 6 and 12 after treatment initiation. Using ROC analysis, lower CLU baseline levels predicted achieving the therapeutic target of low disease activity and remission at months 3, 6 and 12. In summary, we found increased serum concentrations of clusterin in treatment-naïve patients with early rheumatoid arthritis, and we suggest clusterin as a predictive biomarker of disease activity and treatment response.
format	article
author	Tereza Kropáčková Heřman Mann Olga Růžičková Olga Šléglová Lucia Vernerová Veronika Horváthová Michal Tomčík Karel Pavelka Jiří Vencovský Ladislav Šenolt
author_facet	Tereza Kropáčková Heřman Mann Olga Růžičková Olga Šléglová Lucia Vernerová Veronika Horváthová Michal Tomčík Karel Pavelka Jiří Vencovský Ladislav Šenolt
author_sort	Tereza Kropáčková
title	Clusterin serum levels are elevated in patients with early rheumatoid arthritis and predict disease activity and treatment response
title_short	Clusterin serum levels are elevated in patients with early rheumatoid arthritis and predict disease activity and treatment response
title_full	Clusterin serum levels are elevated in patients with early rheumatoid arthritis and predict disease activity and treatment response
title_fullStr	Clusterin serum levels are elevated in patients with early rheumatoid arthritis and predict disease activity and treatment response
title_full_unstemmed	Clusterin serum levels are elevated in patients with early rheumatoid arthritis and predict disease activity and treatment response
title_sort	clusterin serum levels are elevated in patients with early rheumatoid arthritis and predict disease activity and treatment response
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/227e667eadb7435baccf2f0805b6c601
work_keys_str_mv	AT terezakropackova clusterinserumlevelsareelevatedinpatientswithearlyrheumatoidarthritisandpredictdiseaseactivityandtreatmentresponse AT hermanmann clusterinserumlevelsareelevatedinpatientswithearlyrheumatoidarthritisandpredictdiseaseactivityandtreatmentresponse AT olgaruzickova clusterinserumlevelsareelevatedinpatientswithearlyrheumatoidarthritisandpredictdiseaseactivityandtreatmentresponse AT olgasleglova clusterinserumlevelsareelevatedinpatientswithearlyrheumatoidarthritisandpredictdiseaseactivityandtreatmentresponse AT luciavernerova clusterinserumlevelsareelevatedinpatientswithearlyrheumatoidarthritisandpredictdiseaseactivityandtreatmentresponse AT veronikahorvathova clusterinserumlevelsareelevatedinpatientswithearlyrheumatoidarthritisandpredictdiseaseactivityandtreatmentresponse AT michaltomcik clusterinserumlevelsareelevatedinpatientswithearlyrheumatoidarthritisandpredictdiseaseactivityandtreatmentresponse AT karelpavelka clusterinserumlevelsareelevatedinpatientswithearlyrheumatoidarthritisandpredictdiseaseactivityandtreatmentresponse AT jirivencovsky clusterinserumlevelsareelevatedinpatientswithearlyrheumatoidarthritisandpredictdiseaseactivityandtreatmentresponse AT ladislavsenolt clusterinserumlevelsareelevatedinpatientswithearlyrheumatoidarthritisandpredictdiseaseactivityandtreatmentresponse
_version_	1718385378974498816

Clusterin serum levels are elevated in patients with early rheumatoid arthritis and predict disease activity and treatment response

Ejemplares similares